Hospital Universitario Puerta de Hierro Majadahonda, CIBERCV, Manuel de Falla, 2. Majadahonda, 28222, Madrid, Spain.
Hospital Universitario de Bellvitge, Barcelona, Spain.
J Cardiovasc Transl Res. 2021 Oct;14(5):948-950. doi: 10.1007/s12265-020-10097-2. Epub 2021 Jan 20.
Identification of Anderson-Fabry disease (AFD) in cardiac patients has been restricted so far to patients with left ventricular hypertrophy. Coronary microvascular dysfunction has been described in AFD with and without cardiac hypertrophy and may represent the only manifestation in AFD patients, offering a possible earlier diagnosis. We studied the prevalence of AFD in 663 patients with chest pain with normal or non-obstructive coronary arteries. The overall prevalence of AFD in this cohort was only 0.15% (1/663). AFD is not a frequent cause of chest pain without obstructive coronary artery disease and screening efforts should not be conducted in this patient population.
目前，在心脏患者中，安德森-法布里病（AFD）的鉴定仅限于左心室肥厚的患者。已有研究表明，无论是否存在心肌肥厚，AFD 都会导致冠状动脉微血管功能障碍，且可能是 AFD 患者的唯一表现，为早期诊断提供了可能。我们研究了 663 例胸痛且冠状动脉正常或无阻塞的患者中 AFD 的患病率。该队列中 AFD 的总患病率仅为 0.15%（1/663）。在无阻塞性冠状动脉疾病的胸痛患者中，AFD 并不是常见病因，因此不应在该患者人群中进行筛查。
